Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3 - PubMed (original) (raw)
Comparative Study
. 2008 Mar 15;180(6):3969-79.
doi: 10.4049/jimmunol.180.6.3969.
Affiliations
- PMID: 18322206
- DOI: 10.4049/jimmunol.180.6.3969
Comparative Study
Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3
Achim K Moesta et al. J Immunol. 2008.
Abstract
Interactions between HLA-C ligands and inhibitory killer cell Ig-like receptors (KIR) control the development and response of human NK cells. This regulatory mechanism is usually described by mutually exclusive interactions of KIR2DL1 with C2 having lysine 80, and KIR2DL2/3 with C1 having asparagine 80. Consistent with this simple rule, we found from functional analysis and binding assays to 93 HLA-A, HLA-B, and HLA-C isoforms that KIR2DL1*003 bound all C2, and only C2, allotypes. The allotypically related KIR2DL2*001 and KIR2DL3*001 interacted with all C1, but they violated the simple rule through interactions with several C2 allotypes, notably Cw*0501 and Cw*0202, and two HLA-B allotypes (B*4601 and B*7301) that share polymorphisms with HLA-C. Although the specificities of the "cross-reactions" were similar for KIR2DL2*001 and KIR2DL3*001, they were stronger for KIR2DL2*001, as were the reactions with C1. Mutagenesis explored the avidity difference between KIR2DL2*001 and KIR2DL3*001. Recombinant mutants mapped the difference to the Ig-like domains, where site-directed mutagenesis showed that the combination, but not the individual substitutions, of arginine for proline 16 in D1 and cysteine for arginine 148 in D2 made KIR2DL2*001 a stronger receptor than KIR2DL3*001. Neither residue 16 or 148 is part of, or near to, the ligand-binding site. Instead, their juxtaposition near the flexible hinge between D1 and D2 suggests that their polymorphisms affect the ligand-binding site by changing the hinge angle and the relative orientation of the two domains. This study demonstrates how allelic polymorphism at sites distal to the ligand-binding site of KIR2DL2/3 has diversified this receptor's interactions with HLA-C.
Similar articles
- Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.
Hilton HG, Vago L, Older Aguilar AM, Moesta AK, Graef T, Abi-Rached L, Norman PJ, Guethlein LA, Fleischhauer K, Parham P. Hilton HG, et al. J Immunol. 2012 Aug 1;189(3):1418-30. doi: 10.4049/jimmunol.1100431. Epub 2012 Jul 6. J Immunol. 2012. PMID: 22772445 Free PMC article. - Polymorphic HLA-C Receptors Balance the Functional Characteristics of KIR Haplotypes.
Hilton HG, Guethlein LA, Goyos A, Nemat-Gorgani N, Bushnell DA, Norman PJ, Parham P. Hilton HG, et al. J Immunol. 2015 Oct 1;195(7):3160-70. doi: 10.4049/jimmunol.1501358. Epub 2015 Aug 26. J Immunol. 2015. PMID: 26311903 Free PMC article. - Allelic variation in KIR2DL3 generates a KIR2DL2-like receptor with increased binding to its HLA-C ligand.
Frazier WR, Steiner N, Hou L, Dakshanamurthy S, Hurley CK. Frazier WR, et al. J Immunol. 2013 Jun 15;190(12):6198-208. doi: 10.4049/jimmunol.1300464. Epub 2013 May 17. J Immunol. 2013. PMID: 23686481 Free PMC article. - Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition.
Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Winter CC, et al. J Immunol. 1998 Jul 15;161(2):571-7. J Immunol. 1998. PMID: 9670929 - Tuning of human NK cells by endogenous HLA-C expression.
Goodson-Gregg FJ, Krepel SA, Anderson SK. Goodson-Gregg FJ, et al. Immunogenetics. 2020 May;72(4):205-215. doi: 10.1007/s00251-020-01161-x. Epub 2020 Mar 26. Immunogenetics. 2020. PMID: 32219494 Free PMC article. Review.
Cited by
- High-resolution KIR and HLA genotyping in three Chinese ethnic minorities reveals distinct origins.
Tao S, Norman PJ, You X, Kichula KM, Dong L, Chen N, He Y, Chen C, Zhang W, Zhu F. Tao S, et al. HLA. 2024 Apr;103(4):e15482. doi: 10.1111/tan.15482. HLA. 2024. PMID: 38625090 - HLA class I NK-epitopes and KIR diversities in patients with multiple myeloma.
Beelen NA, Molenbroeck SJJ, Groeneveld L, Voorter CE, Bos GMJ, Wieten L. Beelen NA, et al. Immunogenetics. 2024 Jun;76(3):155-164. doi: 10.1007/s00251-024-01336-w. Epub 2024 Mar 13. Immunogenetics. 2024. PMID: 38478091 Free PMC article. - Donor KIR2DL1 Allelic Polymorphism Influences Posthematopoietic Progenitor Cell Transplantation Outcomes in the T Cell Depleted and Reduced Intensity Conditioning Setting.
Wright PA, van de Pasch LAL, Dignan FL, Kichula KM, Pollock NR, Norman PJ, Marchan E, Hill L, Vandelbosch S, Fullwood C, Sheldon S, Hampson L, Tholouli E, Poulton KV. Wright PA, et al. Transplant Cell Ther. 2024 May;30(5):488.e1-488.e15. doi: 10.1016/j.jtct.2024.02.014. Epub 2024 Feb 17. Transplant Cell Ther. 2024. PMID: 38369017 - The Impact of Second-Shell Nucleotides on Ligand Specificity in Cyclic Dinucleotide Riboswitches.
Barth KM, Hiller DA, Strobel SA. Barth KM, et al. Biochemistry. 2024 Feb 8:10.1021/acs.biochem.3c00586. doi: 10.1021/acs.biochem.3c00586. Online ahead of print. Biochemistry. 2024. PMID: 38329042 - Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab.
Lorig-Roach N, Harpell NM, DuBois RM. Lorig-Roach N, et al. Sci Rep. 2024 Jan 7;14(1):742. doi: 10.1038/s41598-023-50262-6. Sci Rep. 2024. PMID: 38185735 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous